Loading...
Pharmacological inhibition of Hippo pathway, with the novel kinase inhibitor XMU‐MP‐1, protects the heart against adverse effects during pressure overload
BACKGROUND AND PURPOSE: The Hippo pathway has emerged as a potential therapeutic target to control pathological cardiac remodelling. The core components of the Hippo pathway, mammalian Ste‐20 like kinase 1 (Mst1) and mammalian Ste‐20 like kinase 2 (Mst2), modulate cardiac hypertrophy, apoptosis, and...
Na minha lista:
| Udgivet i: | Br J Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6811740/ https://ncbi.nlm.nih.gov/pubmed/31328787 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14795 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|